Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-005 in complement-mediated kidney disease
NCT07363265Phase 2Not yet recruiting
- Sponsor
- LongBio Pharma
- Start
- Feb 2026
- Primary completion
- Aug 2028
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of LP-005 in complement-mediated kidney disease, sponsored by LongBio Pharma. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
LP-005
03
Conditions
complement-mediated kidney disease
Beyond the preview
Go deeper on NCT07363265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07363265.